The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
The startup’s AI platform uses AI algorithms to automatically detect abnormalities and diseases in medical images, reducing patient misdiagnosis and increasing radiologists’ productivity
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Three new molecular diagnostic test panels for influenza and other common respiratory illnesses can be run together or alone using one patient sample
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
The investment will be used to develop affordable Point of Care labs with 70+ tests. Mylab will start deploying systems with its lab partners from Nov 2021
The investment will be used to develop affordable Point of Care labs with 70+ tests. Mylab will start deploying systems with its lab partners from Nov 2021
Subscribe To Our Newsletter & Stay Updated
